

Musa Yilmaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4549249/publications.pdf>

Version: 2024-02-01

74
papers

2,165
citations

236833

25
h-index

243529

44
g-index

74
all docs

74
docs citations

74
times ranked

1972
citing authors

#	ARTICLE	IF	CITATIONS
1	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	2.2	201
2	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 240-248.	5.1	192
3	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
4	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
5	Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 67-75.	2.0	87
6	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561.	2.2	81
7	Acute promyelocytic leukemia current treatment algorithms. <i>Blood Cancer Journal</i> , 2021, 11, 123.	2.8	80
8	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70
9	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	2.0	68
10	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. <i>Blood Cancer Journal</i> , 2019, 9, 7.	2.8	64
11	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
12	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Cancer</i> , 2015, 121, 3894-3904.	2.0	61
13	Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic phase chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 2740-2747.	2.0	61
14	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
15	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
16	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	2.0	50
17	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
18	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48

#	ARTICLE	IF	CITATIONS
19	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	2.5	37
20	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
21	Free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	2.0	33
22	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
23	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
24	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
25	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	1.2	28
26	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
27	The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 253-261.	1.1	25
28	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
29	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24
30	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	2.0	24
31	Gilteritinib clinical activity in relapsed/refractory FLT3-mutated acute myeloid leukemia previously treated with FLT3 inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	2.0	21
32	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1767-1774.	0.6	20
33	Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
34	Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. <i>Seminars in Oncology</i> , 2015, 42, 876-886.	0.8	18
35	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	6.9	18
36	Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	2.0	14
38	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7041-7041.	0.8	12
39	Phase 2 study of hyper-CVAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	2.0	10
40	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 7-16.	1.2	9
41	Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 145-157.	1.2	8
42	How low is too low: Statin induced hemolysis. <i>American Journal of Hematology</i> , 2016, 91, 267-267.	2.0	7
43	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq1,1 0.784314 rgBT 0,8 7	1.1	7
44	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
45	Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 693-699.	0.2	6
46	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 663-667.	0.8	6
47	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7539-7539.	0.8	6
48	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , 2019, 94, E188-E190.	2.0	4
49	Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2021, 39, e19019-e19019.	0.8	4
50	Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI). <i>Blood</i> , 2013, 122, 1488-1488.	0.6	4
51	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	2.0	4
52	<sc>FLT3</sc> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <sc>Acute Myeloid Leukemia</sc> with very low <sc>FLT3</sc> allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279.	2.0	3
53	Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 751-758.	0.9	3
54	The potential role of Bi-specific antibodies in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101218.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	2
56	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. <i>Blood</i> , 2016, 128, 3975-3975.	0.6	2
57	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 757-757.	0.6	2
58	Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7051-7051.	0.8	2
59	Managing patients with myelofibrosis and thrombocytopenia. <i>Expert Review of Hematology</i> , 2022, , 1-9.	1.0	2
60	Prolapsed Gastric Gastrointestinal Stromal Tumor: A Rare Cause of Biliary Obstruction and Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e35-e36.	2.4	1
61	Current and emerging treatments for acute promyelocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 453-461.	0.5	1
62	Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. <i>Blood</i> , 2015, 126, 1335-1335.	0.6	1
63	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. <i>Blood</i> , 2016, 128, 2916-2916.	0.6	1
64	Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. <i>Blood Advances</i> , 2023, 7, 828-831.	2.5	1
65	The changing electrocardiogram in Brugada syndrome. <i>International Journal of Cardiology</i> , 2013, 163, e36-e37.	0.8	0
66	Characteristics and outcomes of patients diagnosed with DNMT3A mutated acute myeloblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19018-e19018.	0.8	0
67	Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. <i>Blood</i> , 2015, 126, 2496-2496.	0.6	0
68	The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3771-3771.	0.6	0
69	Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. <i>Blood</i> , 2015, 126, 3722-3722.	0.6	0
70	Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3720-3720.	0.6	0
71	Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7018-7018.	0.8	0
72	Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7064-7064.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period.. Journal of Clinical Oncology, 2018, 36, 7022-7022.	0.8	0
74	Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.. Journal of Clinical Oncology, 2018, 36, 7053-7053.	0.8	0